Genpep Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.00 Cr
as on 16-11-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.90 Cr
as on 16-11-2024
- Revenue 13601.71%
(FY 2023)
- Profit 22.78%
(FY 2023)
- Ebitda 1116.46%
(FY 2023)
- Net Worth -79.39%
(FY 2023)
- Total Assets 92.71%
(FY 2023)
About Genpep Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹9.90 Cr.
Sanjay Patil, Adinath Jain, Aashay Patel, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24299GJ2021PTC122976
- Company No.
122976
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2021
- Date of AGM
09 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Genpep Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Patil  | Director | 31-Jan-2022 | Current |
| Adinath Jain | Director | 31-Jan-2022 | Current |
| Aashay Patel | Director | 09-Nov-2021 | Current |
| Hemal Patel | Additional Director | 06-Feb-2024 | Current |
| Mahesh Sonar | Director | 10-Aug-2021 | Current |
Financial Performance of Genpep Pharmaceuticals.
Genpep Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13601.71% increase. The company also saw a substantial improvement in profitability, with a 22.78% increase in profit. The company's net worth observed a substantial decline by a decrease of 79.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genpep Pharmaceuticals?
In 2023, Genpep Pharmaceuticals had a promoter holding of 81.00% and a public holding of 19.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maharshi Pharma Chem Private LimitedActive 26 years 3 monthsAashay Patel and Hemal Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 01 Aug 2023 | ₹9.90 Cr | Open |
How Many Employees Work at Genpep Pharmaceuticals?
Genpep Pharmaceuticals has a workforce of 13 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genpep Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genpep Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
